DOCSLIB.ORG

Surfactant Replacement Therapy for Preterm and Term Neonates with Respiratory Distress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Surfactant Replacement Therapy for Preterm and Term Neonates with Respiratory Distress Guidance for the Clinician in Rendering Pediatric Care CLINICAL REPORT Surfactant Replacement Therapy for Preterm and Term Neonates With Respiratory Distress Richard A. Polin, MD, FAAP, Waldemar A. Carlo, MD, FAAP, abstract and COMMITTEE ON FETUS AND NEWBORN Respiratory failure secondary to surfactant deficiency is a major cause KEY WORDS surfactant, antenatal steroids, respiratory distress syndrome, of morbidity and mortality in preterm infants. Surfactant therapy sub- meconium aspiration syndrome, neonatal pneumonia, neonatal stantially reduces mortality and respiratory morbidity for this popu- sepsis, congenital diaphragmatic hernia, pulmonary hemorrhage, lation. Secondary surfactant deficiency also contributes to acute persistent pulmonary hypertension, preterm, term respiratory morbidity in late-preterm and term neonates with meco- ABBREVIATIONS nium aspiration syndrome, pneumonia/sepsis, and perhaps pulmonary BPD—bronchopulmonary dysplasia hemorrhage; surfactant replacement may be beneficial for these in- CI—confidence interval CPAP—continuous positive airway pressure fants. This statement summarizes the evidence regarding indications, ECMO—extracorporeal membrane oxygenation administration, formulations, and outcomes for surfactant-replacement INSURE—intubation, surfactant administration, and extubation therapy. The clinical strategy of intubation, surfactant administra- LOE—level of evidence — fi tion, and extubation to continuous positive airway pressure and NNTB number needed to bene t RDS—respiratory distress syndrome the effect of continuous positive airway pressure on outcomes RR—relative risk and surfactant use in preterm infants are also reviewed. Pediatrics SP-B—surfactant protein B 2014;133:156–163 This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through INTRODUCTION a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any Surfactant replacement was established as an effective and safe commercial involvement in the development of the content of therapy for immaturity-related surfactant deficiency by the early this publication. 1990s.1 Systematic reviews of randomized, controlled trials confirmed The guidance in this report does not indicate an exclusive that surfactant administration in preterm infants with established course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be respiratory distress syndrome (RDS) reduces mortality, decreases the appropriate. incidence of pulmonary air leak (pneumothoraces and pulmonary interstitial emphysema), and lowers the risk of chronic lung disease or death at 28 days of age (Table 1).2–11 Subsequent trials indicated that prophylactic or early administration of surfactant resulted in fewer pneumothoraces, less pulmonary interstitial emphysema, and improved survival without bronchopulmonary dysplasia (BPD). How- ever, recent randomized clinical trials indicate that the benefits of prophylactic surfactant are no longer evident in groups of infants when continuous positive airway pressure (CPAP) is used routinely.5 This clinical report updates a 2008 report from the American Academy of www.pediatrics.org/cgi/doi/10.1542/peds.2013-3443 Pediatrics.1 As in the previous report, a number of clinically important doi:10.1542/peds.2013-3443 topics are reviewed surrounding use of surfactant, including pro- All clinical reports from the American Academy of Pediatrics phylactic versus rescue replacement, preparations and administration automatically expire 5 years after publication unless reaffirmed, techniques, the synergistic effects of surfactant and antenatal steroids, revised, or retired at or before that time. and surfactant therapy for respiratory disorders other than RDS. In PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). addition, the effect of CPAP on RDS and surfactant replacement and the Copyright © 2014 by the American Academy of Pediatrics 156 FROM THE AMERICAN ACADEMY OF PEDIATRICS Downloaded from www.aappublications.org/news by guest on September 29, 2021 FROM THE AMERICAN ACADEMY OF PEDIATRICS TABLE 1 Meta-analyses of Surfactant Replacement: Prophylaxis and Rescue Treatment With prophylactic surfactant versus rescue 2,3,8,11 Animal-Derived and Synthetic Surfactant surfactant.14 However, when the studies Outcome Prophylactic Surfactant Rescue Surfactant that allowed for routine application of Animal Derived Synthetic Animal Derived Synthetic CPAP were included in the meta-analysis N RR (95% CI) N RR (95% CI) N RR (95% CI) N RR (95% CI) (National Institute of Child Health and Human Development SUPPORT Trial and Neonatal mortality 8 0.60 (0.47–0.77) 7 0.70 (0.58–0.85) 10 0.68 (0.57–0.82) 6 0.73 (0.61–0.88) Pneumothorax 9 0.40 (0.29–0.54) 6 0.67 (0.50–0.90) 12 0.42 (0.34–0.52) 5 0.64 (0.55–0.76) Vermont Oxford Network Delivery Room PIE 6 0.46 (0.36–0.59) 2 0.68 (0.50–0.93) 8 0.45 (0.37–0.55) 4 0.62 (0.54–0.71) Management Trial), the benefits of pro- a BPD 8 0.91 (0.79–1.05) 4 1.06 (0.83–1.36) 12 0.95 (0.84–1.08) 5 0.75 (0.61–0.92) phylactic surfactant on mortality (RR BPD/deatha 8 0.80 (0.72–0.88) 4 0.89 (0.77–1.03) 12 0.83 (0.77–0.90) 4 0.73 (0.65–0.83) 0.89; 95% CI 0.76–1.04) and air leak (RR N, number; PIE, pulmonary interstitial emphysema. a Defined at 28 d. 0.86; 95% CI 0.71–1.04) could no longer be demonstrated.5 Furthermore, infants receiving prophylactic surfactant had efficacy of the INSURE approach (intuba- born at less than 27 weeks’ gestation, tion, surfactant administration, and ex- may be increased with surfactant a higher incidence of BPD or death than tubation to CPAP) are reviewed. therapy. Surfactant replacement is did infants stabilized on CPAP (RR 1.12; 95% CI 1.02–1.24). Secondary analyses effective for larger and more mature of studies that did or did not use CPAP PRETERM INFANTS AND preterm infants with established RDS. SURFACTANT EFFECTIVENESS IN to stabilize infants demonstrated a trend to a lower risk of intraventricular CLINICAL TRIALS PROPHYLACTIC VERSUS RESCUE – SURFACTANT hemorrhage (RR 0.91; 95% CI 0.82 1.00) Surfactant trials have included infants and severe intraventricular hemorrhage born between 23 and 34 weeks’ ges- A prophylactic, or preventive, surfactant (RR 0.87; 95% CI 0.70–1.04) with pro- tation and/or with birth weight be- strategy is defined as intubation and phylactic surfactant. That finding cannot tween 500 and 2000 g.1–12 The results surfactant administration to infants at be explained; however, there was con- of subgroup analyses from such stud- high risk of developing RDS for the siderable heterogeneity in the trials in- ies indicated that surfactant therapy primary purpose of preventing wors- cluded in the meta-analysis. The risks of decreased mortality rates most effec- ening RDS rather than treatment of developing other complications of pre- tively in infants born at less than 30 established RDS; this has been oper- maturity, such as retinopathy of pre- weeks’ gestation or with birth weight ationalized in clinical studies as sur- maturity, patent ductus arteriosus, and <1250 g.12 In addition, surfactant re- factant administration in the delivery periventricular leukomalacia, were not placement reduced the incidence of room before initial resuscitation efforts significantly different. pneumothorax, pulmonary interstitial or the onset of respiratory distress or, When studies investigating infants born emphysema, and the combined out- most commonly, after initial re- at <30 weeks’ gestation were analyzed come of death or BPD, compared with suscitation but within 10 to 30 minutes separately,5 similar findings were no surfactant replacement12;these after birth. This contrasts with a rescue noted. However, there was a trend for findings suggest that lung injury is or treatment surfactant strategy, in an increased risk of chronic lung dis- mitigated after surfactant replace- which surfactant is given only to pre- ease in infants born at <30 weeks’ ment. The incidence of other medical term infants with established RDS. gestation who received prophylactic morbidities, such as BPD, intraven- Rescue surfactant is most often ad- surfactant (RR 1.13; 95% CI 1.00–1.28) tricular hemorrhage, necrotizing en- ministered within the first 12 hours and a significant increase in death or terocolitis, health care–associated after birth, when specified threshold chronic lung disease (RR 1.13; 95% CI infections, retinopathy of prematurity, 1.02–1.25) with use of prophylactic and patent ductus arteriosus, has not criteria of severity of RDS are met. surfactant. changed with surfactant replacement, The meta-analysis of studies conducted but this may be attributable, in part, before routine application of CPAP EARLY VERSUS DELAYED to the large reduction in mortality demonstrated a lower mortality rate SELECTIVE SURFACTANT with surfactant replacement ther- (relative risk [RR] 0.69; 95% confidence TREATMENT OF RDS apy.13 The onset of clinical signs of interval [CI] 0.56–0.85; number needed patent ductus arteriosus may occur to benefit [NNTB] 20) and a decrease in Although there are no statistically earlier, and the incidence of pulmo- the risk of air leak (RR 0.79; 95% CI significant benefits to prophylactic use nary hemorrhage, especially in infants 0.63–0.98) in preterm infants receiving of surfactant when compared with PEDIATRICS Volume 133, Number 1, January 2014 157 Downloaded from www.aappublications.org/news by guest on September 29, 2021 prophylactic CPAP, several studies have CPAP without surfactant.15 When com- of surfactant protein B (SP-B). SP-B investigated whether administration of pared with the group of infants re- enhances the rate of adsorption of surfactant early in the course of re- ceiving prophylactic surfactant and phospholipids at the air-water inter- spiratory insufficiency improves clini- continued ventilation, the RR of death face, is involved in the formation of tu- cal outcomes.
Load more

Recommended publications
  • Effects of Surfactants on the Toxicitiy of Glyphosate, with Specific Reference to RODEO
    SERA TR 97-206-1b Effects of Surfactants on the Toxicitiy of Glyphosate, with Specific Reference to RODEO Submitted to: Leslie Rubin, COTR Animal and Plant Health Inspection Service (APHIS) Biotechnology, Biologics and Environmental Protection Environmental Analysis and Documentation United States Department of Agriculture Suite 5A44, Unit 149 4700 River Road Riverdale, MD 20737 Task No. 5 USDA Contract No. 53-3187-5-12 USDA Order No. 43-3187-7-0028 Prepared by: Gary L. Diamond Syracuse Research Corporation Merrill Lane Syracuse, NY 13210 and Patrick R. Durkin Syracuse Environmental Research Associates, Inc. 5100 Highbridge St., 42C Fayetteville, New York 13066-0950 Telephone: (315) 637-9560 Fax: (315) 637-0445 CompuServe: 71151,64 Internet: [email protected] February 6, 1997 TABLE OF CONTENTS EXECUTIVE SUMMARY ......................................... iii 1. INTRODUCTION .............................................1 2. CONSTITUENTS OF SURFACTANT FORMULATIONS USED WITH RODE0 ....4 2.1. AGRI-DEX ..........................................4 2.2. LI-700 .............................................4 2.3. R-11 ...............................................6 2.4. LATRON AG-98 ......................................6 2.5. LATRON AG-98 AG ....................................7 3. INFORMATION ON EFFECTS OF SURFACTANT FORMULATIONS ON THE TOXICITY OF RODEO ................................8 3.1. HUMAN HEALTH ......................................8 3.1.1. LI 700 ........................................8 3.1.2. Phosphatidylcholine ................................8
    [Show full text]
  • Pulmonary Surfactant: the Key to the Evolution of Air Breathing Christopher B
    Pulmonary Surfactant: The Key to the Evolution of Air Breathing Christopher B. Daniels and Sandra Orgeig Department of Environmental Biology, University of Adelaide, Adelaide, South Australia 5005, Australia Pulmonary surfactant controls the surface tension at the air-liquid interface within the lung. This sys- tem had a single evolutionary origin that predates the evolution of the vertebrates and lungs. The lipid composition of surfactant has been subjected to evolutionary selection pressures, partic- ularly temperature, throughout the evolution of the vertebrates. ungs have evolved independently on several occasions pendent units, do not necessarily stretch upon inflation but Lover the past 300 million years in association with the radi- unpleat or unfold in a complex manner. Moreover, the many ation and diversification of the vertebrates, such that all major fluid-filled corners and crevices in the alveoli open and close vertebrate groups have members with lungs. However, lungs as the lung inflates and deflates. differ considerably in structure, embryological origin, and Surfactant in nonmammals exhibits an antiadhesive func- function between vertebrate groups. The bronchoalveolar lung tion, lining the interface between apposed epithelial surfaces of mammals is a branching “tree” of tubes leading to millions within regions of a collapsed lung. As the two apposing sur- of tiny respiratory exchange units, termed alveoli. In humans faces peel apart, the lipids rise to the surface of the hypophase there are ~25 branches and 300 million alveoli. This structure fluid at the expanding gas-liquid interface and lower the sur- allows for the generation of an enormous respiratory surface face tension of this fluid, thereby decreasing the work required area (up to 70 m2 in adult humans).
    [Show full text]
  • Henry's Law Constants and Micellar Partitioning of Volatile Organic
    38 J. Chem. Eng. Data 2000, 45, 38-47 Henry’s Law Constants and Micellar Partitioning of Volatile Organic Compounds in Surfactant Solutions Leland M. Vane* and Eugene L. Giroux United States Environmental Protection Agency, National Risk Management Research Laboratory, 26 West Martin Luther King Drive, Cincinnati, Ohio 45268 Partitioning of volatile organic compounds (VOCs) into surfactant micelles affects the apparent vapor- liquid equilibrium of VOCs in surfactant solutions. This partitioning will complicate removal of VOCs from surfactant solutions by standard separation processes. Headspace experiments were performed to quantify the effect of four anionic surfactants and one nonionic surfactant on the Henry’s law constants of 1,1,1-trichloroethane, trichloroethylene, toluene, and tetrachloroethylene at temperatures ranging from 30 to 60 °C. Although the Henry’s law constant increased markedly with temperature for all solutions, the amount of VOC in micelles relative to that in the extramicellar region was comparatively insensitive to temperature. The effect of adding sodium chloride and isopropyl alcohol as cosolutes also was evaluated. Significant partitioning of VOCs into micelles was observed, with the micellar partitioning coefficient (tendency to partition from water into micelle) increasing according to the following series: trichloroethane < trichloroethylene < toluene < tetrachloroethylene. The addition of surfactant was capable of reversing the normal sequence observed in Henry’s law constants for these four VOCs. Introduction have long taken advantage of the high Hc values for these compounds. In the engineering field, the most common Vast quantities of organic solvents have been disposed method of dealing with chlorinated solvents dissolved in of in a manner which impacts human health and the groundwater is “pump & treat”swithdrawal of ground- environment.
    [Show full text]
  • Dive Theory Guide
    DIVE THEORY STUDY GUIDE by Rod Abbotson CD69259 © 2010 Dive Aqaba Guidelines for studying: Study each area in order as the theory from one subject is used to build upon the theory in the next subject. When you have completed a subject, take tests and exams in that subject to make sure you understand everything before moving on. If you try to jump around or don’t completely understand something; this can lead to gaps in your knowledge. You need to apply the knowledge in earlier sections to understand the concepts in later sections... If you study this way you will retain all of the information and you will have no problems with any PADI dive theory exams you may take in the future. Before completing the section on decompression theory and the RDP make sure you are thoroughly familiar with the RDP, both Wheel and table versions. Use the appropriate instructions for use guides which come with the product. Contents Section One PHYSICS ………………………………………………page 2 Section Two PHYSIOLOGY………………………………………….page 11 Section Three DECOMPRESSION THEORY & THE RDP….……..page 21 Section Four EQUIPMENT……………………………………………page 27 Section Five SKILLS & ENVIRONMENT…………………………...page 36 PHYSICS SECTION ONE Light: The speed of light changes as it passes through different things such as air, glass and water. This affects the way we see things underwater with a diving mask. As the light passes through the glass of the mask and the air space, the difference in speed causes the light rays to bend; this is called refraction. To the diver wearing a normal diving mask objects appear to be larger and closer than they actually are.
    [Show full text]
  • Biomechanics of Safe Ascents Workshop
    PROCEEDINGS OF BIOMECHANICS OF SAFE ASCENTS WORKSHOP — 10 ft E 30 ft TIME AMERICAN ACADEMY OF UNDERWATER SCIENCES September 25 - 27, 1989 Woods Hole, Massachusetts Proceedings of the AAUS Biomechanics of Safe Ascents Workshop Michael A. Lang and Glen H. Egstrom, (Editors) Copyright © 1990 by AMERICAN ACADEMY OF UNDERWATER SCIENCES 947 Newhall Street Costa Mesa, CA 92627 All Rights Reserved No part of this book may be reproduced in any form by photostat, microfilm, or any other means, without written permission from the publishers Copies of these Proceedings can be purchased from AAUS at the above address This workshop was sponsored in part by the National Oceanic and Atmospheric Administration (NOAA), Department of Commerce, under grant number 40AANR902932, through the Office of Undersea Research, and in part by the Diving Equipment Manufacturers Association (DEMA), and in part by the American Academy of Underwater Sciences (AAUS). The U.S. Government is authorized to produce and distribute reprints for governmental purposes notwithstanding the copyright notation that appears above. Opinions presented at the Workshop and in the Proceedings are those of the contributors, and do not necessarily reflect those of the American Academy of Underwater Sciences PROCEEDINGS OF THE AMERICAN ACADEMY OF UNDERWATER SCIENCES BIOMECHANICS OF SAFE ASCENTS WORKSHOP WHOI/MBL Woods Hole, Massachusetts September 25 - 27, 1989 MICHAEL A. LANG GLEN H. EGSTROM Editors American Academy of Underwater Sciences 947 Newhall Street, Costa Mesa, California 92627 U.S.A. An American Academy of Underwater Sciences Diving Safety Publication AAUSDSP-BSA-01-90 CONTENTS Preface i About AAUS ii Executive Summary iii Acknowledgments v Session 1: Introductory Session Welcoming address - Michael A.
    [Show full text]
  • Effect of Surfactant on Interfacial Gas Transfer Studied by Axisymmetric Drop Shape Analysis-Captive Bubble (ADSA-CB)
    5446 Langmuir 2005, 21, 5446-5452 Effect of Surfactant on Interfacial Gas Transfer Studied by Axisymmetric Drop Shape Analysis-Captive Bubble (ADSA-CB) Yi Y. Zuo,† Dongqing Li,† Edgar Acosta,‡ Peter N. Cox,§ and A. Wilhelm Neumann*,† Department of Mechanical and Industrial Engineering, University of Toronto, 5 King’s College Road, Toronto, ON, M5S 3G8, Canada, Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, ON, M5S 3E5, Canada, and Department of Critical Care Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada Received January 31, 2005. In Final Form: April 3, 2005 A new method combining axisymmetric drop shape analysis (ADSA) and a captive bubble (CB) is proposed to study the effect of surfactant on interfacial gas transfer. In this method, gas transfer from a static CB to the surrounding quiescent liquid is continuously recorded for a short period (i.e., 5 min). By photographical analysis, ADSA-CB is capable of yielding detailed information pertinent to the surface tension and geometry of the CB, e.g., bubble area, volume, curvature at the apex, and the contact radius and height of the bubble. A steady-state mass transfer model is established to evaluate the mass transfer coefficient on the basis of the output of ADSA-CB. In this way, we are able to develop a working prototype capable of simultaneously measuring dynamic surface tension and interfacial gas transfer. Other advantages of this method are that it allows for the study of very low surface tensions (<5 mJ/m2) and does not require equilibrium of gas transfer.
    [Show full text]
  • Perspectives on Mucus Secretion in Reef Corals
    MARINE ECOLOGY PROGRESS SERIES Vol. 296: 291–309, 2005 Published July 12 Mar Ecol Prog Ser REVIEW Perspectives on mucus secretion in reef corals B. E. Brown*, J. C. Bythell School of Biology, Newcastle University, Newcastle upon Tyne NE1 7RU, UK ABSTRACT: The coral surface mucus layer provides a vital interface between the coral epithelium and the seawater environment and mucus acts in defence against a wide range of environmental stresses, in ciliary-mucus feeding and in sediment cleansing, amongst other roles. However, we know surpris- ingly little about the in situ physical and chemical properties of the layer, or its dynamics of formation. We review the nature of coral mucus and its derivation and outline the wide array of roles that are pro- posed for mucus secretion in corals. Finally, we review models of the surface mucus layer formation. We argue that at any one time, different types of mucus secretions may be produced at different sites within the coral colony and that mucus layers secreted by the coral may not be single homogeneous layers but consist of separate layers with different properties. This requires a much more dynamic view of mucus than has been considered before and has important implications, not least for bacterial colonisation. Understanding the formation and dynamics of the surface mucus layer under different environmental conditions is critical to understanding a wide range of associated ecological processes. KEY WORDS: Mucin · Mucopolysaccharide · Coral surface microlayer · CSM · Surface mucopolysaccharide layer · SML Resale or republication not permitted without written consent of the publisher INTRODUCTION production has been a problem for many working with coral tissues in recent years, and the offending sub- The study of mucus secretion by corals has fascinated stance has to be removed before histological, biochem- scientists for almost a century, from the work of Duer- ical or physiological processing can begin.
    [Show full text]
  • Dive Kit List Intro
    Dive Kit List Intro We realise that for new divers the array of dive equipment available can be slightly daunting! The following guide should help you choose dive gear that is suitable for your Blue Ventures expedition, without going overboard. Each section will highlight features to consider when choosing equipment, taking into account both budget and quality. Diving equipment can be expensive so we don’t want you to invest in something that will turn out to be a waste of money or a liability during your expedition! Contents Must haves Mask Snorkel Fins Booties Exposure protection DSMB and reel Slate and pencils Dive computer Dive manuals Highly recommended Cutting tool Compass Underwater light Optional Regulator BCD Dry bag Extra stuff Contact us Mask Brands: Aqualung, Atomic, Cressi, Hollis, Mares, Oceanic, Scubapro, Tusa Recommended: Cressi Big Eyes. Great quality for a comparatively lower price. http://www.cressi.com/Catalogue/Details.asp?id=17 Oceanic Shadow Mask. Frameless mask, which makes it easy to put flat into your luggage or BCD pocket. http://www.oceanicuk.com/shadow-mask.html Aqualung Linea Mask. Keeps long hair from getting tangled in the buckle while also being frameless. https://www.aqualung.com/us/gear/masks/item/74-linea Tusa neoprene strap cover. Great accessory for your mask in order to keep your hair from getting tangled in the mask and increasing the ease of donning and doffing your mask. http://www.tusa.com/eu-en/Tusa/Accessories/MS-20_MASK_STRAP To be considered: The most important feature when you buy a mask is fit. The best way to find out if it is the right mask for you is to place the mask against your face as if you were wearing it without the strap, and inhaling through your nose.
    [Show full text]
  • What Happens to Herbicides After We Apply Them? by Kyra Clark
    Refuge Notebook • Vol. 19, No. 38 • September 22, 2017 What happens to herbicides after we apply them? by Kyra Clark some of the more than 110 exotic plant species in- troduced to the Kenai Peninsula. Over the years, we have been spot treating invasive plants at trail- heads and boat launches, keeping the refuge notice- ably cleaner than the rest of the peninsula. We typ- ically use three chemicals: glyphosate, aminopyralid and fluridone. These are the active ingredients in the different commercial herbicides we use to control or kill target species. The big differences between DDT and other pesti- cides used in Carson’s time and those we use now are their environmental fate and how they degrade over time. DDT has a half-life (time required for half of the original concentration to degrade) of 2–15 years. DDT can also leach into water sources and bio-accumulate in the tissues of animals. In contrast, the three chem- icals we use all have half-lives under a year, do not leach, and do not bio-accumulate in animals. There has been a lot of bad press about glyphosate, but most issues with glyphosate products are asso- ciated with its use in agriculture where herbicides are applied chronically or genetically encoded into seeds. Glyphosate products vary in their formula- tions of glyphosate, the carrier solution, and surfac- tant. Surfactants enhance the active ingredient’s ef- fectiveness by breaking surface tension of the liquid herbicide to improve its coverage of foliage, its ability to stick to foliage, and its rainfastness. We typically use two glyphosate formulations for terrestrial weed control on the refuge.
    [Show full text]
  • Lipid–Protein and Protein–Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis
    International Journal of Molecular Sciences Review Lipid–Protein and Protein–Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis Olga Cañadas 1,2,Bárbara Olmeda 1,2, Alejandro Alonso 1,2 and Jesús Pérez-Gil 1,2,* 1 Departament of Biochemistry and Molecular Biology, Faculty of Biology, Complutense University, 28040 Madrid, Spain; [email protected] (O.C.); [email protected] (B.O.); [email protected] (A.A.) 2 Research Institut “Hospital Doce de Octubre (imasdoce)”, 28040 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-913944994 Received: 9 May 2020; Accepted: 22 May 2020; Published: 25 May 2020 Abstract: Pulmonary surfactant is a lipid/protein complex synthesized by the alveolar epithelium and secreted into the airspaces, where it coats and protects the large respiratory air–liquid interface. Surfactant, assembled as a complex network of membranous structures, integrates elements in charge of reducing surface tension to a minimum along the breathing cycle, thus maintaining a large surface open to gas exchange and also protecting the lung and the body from the entrance of a myriad of potentially pathogenic entities. Different molecules in the surfactant establish a multivalent crosstalk with the epithelium, the immune system and the lung microbiota, constituting a crucial platform to sustain homeostasis, under health and disease. This review summarizes some of the most important molecules and interactions within lung surfactant and how multiple lipid–protein and protein–protein interactions contribute to the proper maintenance of an operative respiratory surface. Keywords: pulmonary surfactant film; surfactant metabolism; surface tension; respiratory air–liquid interface; inflammation; antimicrobial activity; apoptosis; efferocytosis; tissue repair 1.
    [Show full text]
  • Soluble Surfactant and Nanoparticle Effects on Lipid Monolayer Assembly and Stability
    Soluble Surfactant and Nanoparticle Effects on Lipid Monolayer Assembly and Stability Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Matthew D. Nilsen, B.S., M.Sc. Graduate Program in Chemical Engineering The Ohio State University 2010 Dissertation Committee: Dr. James F. Rathman, Advisor Dr. L. James Lee Dr. Isamu Kusaka c Copyright by Matthew D. Nilsen 2010 Abstract The study of self-assembly dynamics that lead to ultra-thin films at an interface remains a very active research topic because of the ability to generate interesting and useful structures that can perform specific tasks such as aiding in magnetic separa- tions, acting as two-dimensional biosensors and the modification of surfaces without changing their morphology. In some cases this is critical to surface functionality. This area is also important because it may ultimately yield simple screening techniques for novel surfactants and nanoparticle species before they are introduced onto the market, as is already happening. In the work presented here we studied the assembly dynamics of the insoluble lipid DPPC, common to most mammalian cell lines, in the presence of soluble surfactant and nanoparticle species. Preliminarily, we investigated the anomalous behavior of soluble surfactants at the air/water interface as an exten- sion to work done previously and then used these results in an attempt to explain the behavior of the combined surfactant/lipid monolayer under dynamic and static conditions. Separately, we performed nanoparticle dynamics studies for a commer- cially available product and for particles created in-house before performing similar statics/dynamics work on the combined nanoparticle/lipid monolayer.
    [Show full text]
  • EUBS2014 Abstractbook.Pdf
    CONFERENCE COMMITTEE Secretary General: Dr. Peter Müller (EUBS/GTÜM) Secretary: P.Freitag (Public Relations Druckkammerzentren Rhein Main Taunus GmbH) Organising Committee: Michael Kemmerer (CEO Druckkammerzentren Rhein Main Taunus GmbH) Dr. Peter Germonpré (EUBS) Dr. Karin Hasmiller (GTÜM) Dr. Dirk Michaelis (Medical Director Druckkammerzentren Rhein Main Taunus GmbH) Scientific Committee: Prof. Costantino Balestra (EUBS) Dr. Lesley Blogg (EUBS) PD Dr. Björn Jüttner (EUBS/GTÜM) PD Dr. Claus-Martin Muth (EUBS/GTÜM) PD Dr. Lars Perlik (Asklepios Paulinen Klinik Wiesbaden) PD Dr. Tim Piepho (GTÜM) Prof. Dr. Christian Werner (University Hospital Mainz) EUBS EXECUTIVE COMMITTEE – SEPT 2014 Prof. Costantino Balestra (President of EUBS) Dr Jacek Kot (Vice President of EUBS) Dr Peter Germonpré (Immediate Past President) Prof Alf O. Brubakk (Past President) Dr Joerg Schmutz (Honorary Secretary) Dr Fiona Sharp (Member at Large) Dr Lesley Blogg (Member at Large) Dr Pierre Lafère (Member at Large) Dr Philip Bryson (Liaison Committee) Dr Peter Muller (DHM Journal, European Editor) Ms Patricia Wooding (Membership Secretary – Treasurer) 1 PARTNERS AND SPONSORS Organisation: Conference Support Grant: Druckkammerzentren Rhein Main Taunus GmbH USN Office of Naval Research Global London, UK Platinum Sponsor: GS Elektromedizinische Geräte G. Stemple GmbH Gold Sponsors: Druckkammerzentren Rhein Main Taunus German Society for Diving- and GmbH Hyperbaric Medicine Haux & Siare Silver Sponsors: Keller Medical GmbH IHC Hytech DAN Europe aqua med OxyHeal Health Group Hipertech Bronze Sponsor: VDD e.V. 2 CORPORATE MEMBERS OF EUBS SCIENTIFIC PROGRAMME OVERVIEW 3 Time Author Title No. Page Tuesday, 23. September 2014 08:00 ‐ 17:00 Registration open & Set‐up Industry Exhibition 12:00 ‐ 17:00 Jacek Kot European Code of Practice in Hyperbaric Medicine, Meeting of the Editorial Task Force 17:00 ‐ 18:00 After Work Industry Exhibition Wednesday, 24.
    [Show full text]